Injection monthly
$158.93
Nasal monthly
$157.91
Quarterly offer
Savings wording does not establish the total invoice

Read the individual pages before the homepage headline

Trava publishes separate product pages for NAD+ injection and NAD+ nasal spray. The checked injection page displays $158.93 monthly, while the nasal page displays $157.91 monthly. Those product-specific labels are the clearest pricing basis available for this review and are kept separate from lower as-low-as figures elsewhere on the storefront.

The provider describes online review by licensed clinicians and fulfillment through pharmacies when a prescription is appropriate. We have not enrolled or evaluated the care received by a patient. The review concerns the published offer and its commercial details, rather than treating the online process itself as evidence of a particular clinical outcome.

The quarterly wording is not a complete invoice

The injection page places a Save $127.86 statement beside its quarterly-package wording. The nasal page similarly shows Save $125.82. The displayed text does not make clear whether the number represents a discount, a monthly equivalent or another selected-plan calculation. We do not multiply either figure into an assumed quarterly charge.

Ask Trava for the exact upfront payment, stated supply, renewal amount and billing interval of the option being considered. Compare that document with the monthly alternative. A lower promotional headline can be useful once its conditions are clear, but it cannot replace the full amount committed or establish that two pages describe identical purchase terms.

The quantity labels need context

Both reviewed NAD+ pages show a 1,000 mg label. For the injection, that does not establish a concentration without the final vial volume. For the nasal product, it does not provide the bottle volume or amount delivered through a particular use. The shared total is therefore not evidence that the two routes are interchangeable.

Request the actual prescription and pharmacy specifications, including storage and beyond-use instructions. Also ask which supplies, assessment and follow-up services are included in each price. The public descriptions are brief, so a reader should not assume a complete care bundle merely because the monthly number appears precise to the cent.

What the provider claims and what remains unverified

Trava describes NAD+ through its role in cellular metabolism and markets the products for wellness. That biological context does not independently prove improved energy, cognition or longevity from either finished preparation. We did not establish a comparative clinical trial of these two products or evidence that one route provides a predictable advantage over the other.

The site discloses that compounded medications are not FDA-approved and require a prescription. Keep that status separate from statements about pharmacy standards or testing. Trava adds two identifiable NAD+ offers with explicit monthly figures; their remaining comparison gaps concern the quarterly invoice, dispensing details and complete care inclusions. Resolve those points in writing before selecting a longer commitment.

Useful distinctions

  • Separate pages and monthly prices for each NAD route
  • Quantity labels available to discuss with the pharmacy
  • Compounded-drug status disclosed

Limitations to weigh

  • Quarterly headline is ambiguous
  • Vial and bottle volumes not established
  • Complete inclusions and clinical outcomes not independently verified

Sources & further reading

Official pages and evidence consulted for this article. Checked October 11, 2026. Provider pages establish advertised terms; they do not independently establish effectiveness.

  1. Trava: NAD+ injection offer Provider
  2. Trava: NAD+ nasal spray offer Provider
  3. Trava: care model and compounding disclosure Provider
  4. FDA: Compounding questions and answers Regulator